Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine (RenovoRx)
- Development stage
- Unknown
- Lead developer
- RenovoRx
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
RenovoGem is a drug-device combination therapy developed by RenovoRx, consisting of the chemotherapy agent gemcitabine delivered via the proprietary RenovoCath micro-catheter using Trans-Arterial Micro-Perfusion (TAMP) technology. This approach is designed to provide targeted, high-concentration delivery of gemcitabine directly to the tumor site through the arterial wall, specifically for the treatment of locally advanced pancreatic adenocarcinoma (LAPC). By utilizing intra-arterial delivery, the system aims to maximize local therapeutic effect while minimizing the systemic toxicities typically associated with intravenous administration. The therapy is currently being evaluated in the Phase 3 TIGeR-PaC clinical trial, comparing it to standard-of-care intravenous gemcitabine and nab-paclitaxel.
- Brand names
- RenovoGem
- Other names
- intra-arterial gemcitabinegemcitabine (TAMP)gemcitabine-RenovoRx
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on gemcitabine (RenovoRx).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine (RenovoRx).